CAJ | 학술논문

肺癌是肿瘤死亡的最常见原因，其中85％为非小细胞肺癌，且大多数患者有晚期的表现，患者5年的生成率仅为1％～5％，近年研发成功的酪氨酸激酶抑制剂，开启了肿瘤小分子靶向治疗的新时代，尤其是由阿斯利康公司研制并推出的吉非替尼，为晚期 NSCLC患者又提供了一种有效的治疗药物。本文对吉非替尼治疗非小细胞肺癌的临床研究进展进行综述，其中包括全球范围内吉非替尼单药二线、一线和维持治疗，以及联合化疗治疗非小细胞肺癌的临床研究进展。
폐암시종류사망적최상견원인，기중85％위비소세포폐암，차대다수환자유만기적표현，환자5년적생성솔부위1％～5％，근년연발성공적락안산격매억제제，개계료종류소분자파향치료적신시대，우기시유아사리강공사연제병추출적길비체니，위만기 NSCLC환자우제공료일충유효적치료약물。본문대길비체니치료비소세포폐암적림상연구진전진행종술，기중포괄전구범위내길비체니단약이선、일선화유지치료，이급연합화료치료비소세포폐암적림상연구진전。
Lung cancer is the most common cause of death,85%of non-small cell lung cancer,and most patients with advanced performance,generating 5-year rate was 1%~5%.In recent years,successfully developed tyrosine ki-nase inhibitors,opened a new era of smallmolecule targeted cancer therapy.Especially the Gefitinib which is devel-oped and launched by Astra Zeneca,provides another effective treatment for patients with advanced NSCLC.This pa-per gived an overview of worldwide clinical studies of Gefitinib in the treatment of non-small cell lung cancer,which included the monotherapy of Gefitinib in first-line, second-line and maintenance treatment, also the combination chemotherapy in non-small cell lung cancer.